Monitor for actual sales volume and pricing under this ATM offering, as sustained dilution could pressure the stock price. The success of the bempikibart clinical program, particularly upcoming topline data in mid-2026, will be a key catalyst that could offset the negative sentiment from dilution.
QTTB drugs
QTTB drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 27 $5.47entry
- T+1 · 7mo ago +4.57%α +5.06% · $5.72
- T+5 · 7mo ago −7.86%α −8.26% · $5.04
- T+20 · 6mo ago +29.62%α +24.66% · $7.09
- T+60 · 4mo ago +175.69%α +170.91% · $15.08
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Q32 Bio Inc. is conducting an at-the-market (ATM) equity offering of up to $75 million in common stock through Cantor Fitzgerald. The company previously raised $14.2 million under a prior ATM agreement, which has now been terminated. The new offering allows for flexible, opportunistic capital raising based on market conditions, with proceeds intended for working capital and advancing its lead drug candidate, bempikibart, into future clinical trials for alopecia areata.
Key Facts
- Q32 Bio is offering up to $75,000,000 in common stock through an at-the-market (ATM) offering with Cantor Fitzgerald.
- The company has already raised $14,200,000 under a prior ATM agreement, which has been terminated.
- The offering is subject to market conditions, with no minimum amount required, and shares will be sold at prevailing market prices.
- Proceeds will be used for working capital, research, clinical development, and commercialization efforts, primarily for advancing bempikibart.
- Investors purchasing shares will experience immediate dilution of $1.77 per share based on a $6.48 offering price.
- The company is a smaller reporting company with a market cap of $95M and is focused on clinical-stage biologics for autoimmune diseases.
Financial Impact
Up to $75 million in gross proceeds, with net proceeds dependent on the number of shares sold and market prices. Investors will face $1.77 per share dilution based on a $6.48 price.
Risk Factors
- Significant shareholder dilution from the issuance of new shares.
- The company has broad discretion over the use of proceeds, which may not lead to value-enhancing outcomes.
- Future sales under the ATM program could depress the stock price if perceived as a sign of financial need.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-177170 |
| Document: 0001193125-26-177170-index-headers.html | 0001193125-26-177170 |
| Document: 0001193125-26-177170-index.html | 0001193125-26-177170 |
| Document: 0001193125-26-177170.txt | 0001193125-26-177170 |
Track record
23 reports on QTTB
3 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +48.47% at T+60 after the Jul 14, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $8.29 Now $8.29 −0.00% settles Dec 16
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $8.47 Now $8.29 −2.13% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $8.71 Now $8.29 −4.82% settles Dec 15
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $9.34 Now $8.29 −11.24% settles Dec 8
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $9.34 Now $8.29 −11.24% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $8.97 Now $8.29 −7.58% settles Dec 3
- Oct 28, 202619d ago SC 13G Neutral 4/10 Entry $9.06 Now $8.29 −8.50% settles Nov 25
- Oct 9, 20265w ago SC 13G Neutral 4/10 Entry $8.74 to $9.36 Now $8.29 −5.15% ▲ +7.09% +10.36% vs SPY
- Sep 30, 20266w ago 8-K Bullish 6/10 Entry $8.27 to $8.71 Now $8.29 +0.24% ▲ +5.32% +4.05% vs SPY
- Sep 14, 20269w ago 8-K Neutral 3/10 Entry $10.91 to $8.74 Now $8.29 −24.01% ▼ −19.89% −22.15% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers